Advertisement
Amylin will be introducing data through over 20 posters and eight oralpresentations at the meeting. The data will demonstrate significant progressin key research and clinical programs that include studies of BYETTA, SYMLIN,and Amylin's early and late-stage pipeline candidates. Additional informationwill be presented during two symposia focused on the multi-hormonal approachto the treatment of diabetes and obesity, and the role of incretin-basedtherapies in type 2 diabetes.
Advertisement
"We are excited to demonstrate advancement in our diabetes and obesitypipeline programs at this year's ADA, particularly with updated data relatedto the once-weekly formulation of exenatide and the combination therapyprogram for obesity," said Daniel M. Bradbury, President and Chief ExecutiveOfficer, Amylin Pharmaceuticals, Inc. "At Amylin, we continually strive towardour mission of Challenging Science and Changing Lives. By challenging sciencewe question conventional thinking, and open the door for truly innovativeapproaches for developing novel, life-changing therapies. This uniqueapproach, paired with our deep expertise in peptide hormones and broadexperience in diabetes markets, has allowed us to continue developingimportant medicines with life-changing therapeutic potential for patients."
A full list of all Amylin abstracts being presented at ADA is availableat: http://scientificsessions.diabetes.org.
INVESTOR PRESENTATION
Amylin will also conduct a webcast for investors to review the informationpresented at ADA on Sunday, June 8 at 7:45 PM PT (10:45 PM ET). The livepresentation will be webcast, and a recording will be made available followingthe event. The webcast and recording will be accessible through Amylin'scorporate Web site, located at http://www.amylin.com. To access the livewebcast, please log on to Amylin's site approximately 15 minutes prior to thepresentation to register and download any necessary audio software.
About SYMLIN
Taken at mealtime, SYMLIN is the first and only amylin mimetic for use inpatients with diabetes treated with mealtime insulin. SYMLIN is a syntheticanalog of human amylin, a naturally occurring hormone that is made in the betacells of the pancreas, the same cells that make insulin. In patients with type2 diabetes who use insulin, and in patients with type 1 diabetes, those cellsin the pancreas are either damaged or destroyed, resulting in reducedsecretion of both insulin and amylin after meals. The use of SYMLINcontributes to glucose control after meals.
SymlinPen(R) (pramlintide acetate) pen-injector devices offer convenientpre-filled SYMLIN administration with simple, fixed dosing to improve mealtimeglucose control. SymlinPen(R) 120 features fixed dosing to deliver 60 or 120micrograms of SYMLIN per dose. SymlinPen(R) 60 features fixed dosing todeliver 15, 30, 45, or 60 micrograms of SYMLIN per dose.
Healthcare professionals and people with diabetes may obtain moreinformation, including the complete Prescribing Information and the MedicationGuide, at http://www.SYMLIN.com.
Important Safety Information for SYMLIN
SYMLIN is not intended for all patients with diabetes. SYML
